About Us
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
|
|
|
ORMP - Oramed Pharmaceutica...| Previous Close | $2.76 | Open | $2.75 |
| Volume | 79.9K | Market Cap | 52.66M |
| Yield | Last Dividend |
| Oramed Pharmaceuticals : Diabetes Market... | 09/15/20 |
| NEW YORK, Sept. 15, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. , a clinical-stage pharmaceutical company focused on the development of oral drug... | |
| Oramed's Diabetes Market Survey Shows St... | 09/15/20 |
| NEW YORK , Sept. 15, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ) (TASE: ORMP) ( www.oramed.com ), a clinical-stage pharmaceutical... | |
| Oramed Reports Positive End of Phase 2 M... | 07/15/20 |
| NEW YORK , July 15, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ) (TASE: ORMP) ( www.oramed.com ), a clinical-stage pharmaceutical ... | |
| Oramed Announces Positive Initial Clinic... | 06/15/20 |
| NEW YORK, June 15, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical comp... | |
| Oramed Pharmaceuticals to Present at the... | 05/05/20 |
| NEW YORK, May 5, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical compan... | |
| Oramed Pharmaceuticals Inc. Announces Pr... | 02/26/20 |
| NEW YORK, Feb. 26, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP), (TASE: ORMP), a clinical-stage pharmaceutical company focused on t... | |
| Oramed Patent in Europe to be Granted fo... | 01/28/20 |
| NEW YORK, Jan. 28, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) and (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical ... | |
| Oramed Elects Dr. Alexander Fleming to S... | 01/23/20 |
| NEW YORK, Jan. 23, 2020 Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on t... | |
| Oramed Appoints Dr. Jay Skyler to Scient... | 01/21/20 |
| NEW YORK, Jan. 21, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical comp... | |
| Oramed Pharmaceuticals : Quarterly repor... | 01/09/20 |
| Salaryof the Original Agreement, the following paragraph is hereby added: As of January 1, 2020, the Executive shall be entitled to a gross monthly sa... | |
| Oramed Pharmaceuticals Issues Letter to ... | 01/09/20 |
| NEW YORK, Jan. 9, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical compa... | |
| The Daily Biotech Pulse: Axovant Surges ... | 12/20/19 |
| The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs D... | |
| ORAMED PHARMACEUTICALS INC. : Stock Mark... | 12/06/19 |
| ORAMED PHARMACEUTICALS INC. : News, information and stories for ORAMED PHARMACEUTICALS INC. | Nasdaq: ORMP | Nasdaq | |
| Oramed Appoints Dr. Arie Mayer to Board ... | 12/05/19 |
| NEW YORK, Dec. 5, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical compa... | |
| Oramed to Present a Scientific Poster at... | 12/02/19 |
| NEW YORK, December 2, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical c... | |
| Oramed Provides Highlights and Data From... | 11/19/19 |
| NEW YORK, Nov. 19, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical comp... | |
| Oramed Pharmaceuticals Inc. (NASDAQ:ORMP... | 08/16/19 |
| It is not uncommon to see companies perform well in the years after insiders buy shares. Unfortunately, there are also??? | |
| Oramed nabs new patent in U.S. | 03/28/19 |
| No summary available. | |
| Oramed up 11% on oral insulin studies in... | 03/26/19 |
| No summary available. | |
| The Math Behind Oramed's Oral Insulin Su... | 02/20/19 |
| No summary available. | |
| CNBC article highlights $35B market oppo... | 12/31/18 |
| No summary available. | |
| CNBC article highlights $35B market oppo... | 12/31/18 |
| No summary available. | |
| Buy rating | 07/13/20 |
| and raises Price Target from $16.00 to $17.00 | |
| Date | 04/12/2019 (AMC) | Est. (EPS/Rev.) | $1.37 |
| Actual (EPS/Rev.) | $2.5B | EPS (TTM) | $??? |
| Total Revenue | $1.3B | Total Liabilities | $2.1B |
| Cost of Revenue | $2.5B | Total cash flow | $3.2 |
| Total Assets | $29.98B |
| % Insider | 12.52% | % Institutional | 76.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Service Name | Trader | % Success | |
|---|---|---|---|
| Tech Trades | Tech Trades | 81.00 % | Follow |
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
We are not a registered investment advisor. All investments involve risk, individual's trading does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. References to specific securities should not be construed as a recommendation to buy or sell that security only mentioned for informational purposes.
